– Syqe Medical, Ltd. and TerrAscend Corp. announced an exclusive distribution agreement to bring Syqe’s flagship product, the SyqeTM Inhaler, to the Canadian market.
– TerrAscend will utilize their platform to both provide high-quality guidance to patients on use of the Syqe device and educate the medical community on the benefits of medical cannabis and the Syqe treatment.
– For the first time ever, the amount of THC in the bloodstream can be accurately controlled in a consistent, repeatable and completely non-invasive fashion.
Leading pharma-tech company Syqe Medical announced a partnership with TerrAscend Corp. to distribute Syqe’s breakthrough flagship medical cannabis smart inhaler, the Syqe Inhaler, to the Canadian market. Syqe’s entrance into the Canadian market comes at an opportune time, with the patient population ever-increasing.
Pharmaceutical-Grade Medical Cannabis Inhaler
Backed by rigorous clinical trials, the Syqe Inhaler is the world’s first metered-dose medical cannabis inhaler to provide predictable, precise and consistent treatment at pharmaceutical standards. Syqe first debuted its product to the Israeli market in June 2019, and through TerrAscend is bringing its breakthrough technology to the Canadian market to ease the suffering of patients dealing with chronic conditions.
Partnership Details
TerrAscend, through its wholly-owned subsidiaries TerrAscend Canada and Solace Health Network, will lead marketing, distribution and sales efforts across Canada. Through Solace Health’s patient-centric online platform and medical coverage assistance, as well as its wide network of medical professionals, TerrAscend is uniquely positioned for success with the Syqe treatment in the Canadian medical cannabis market.
As part of the agreement, TerrAscend will utilize their platform to both provide high-quality guidance to patients on use of the Syqe device and educate the medical community on the benefits of medical cannabis and the Syqe treatment.
The Bigger Picture
A 2018 survey from Health Canada (2018) showed that 71% of Canadians using medical cannabis do so by consuming dry flowers. For the first time ever, this patient population will have an effective alternative that ensures precision dosing while eliminating the hazards of smoking.
Syqe’s inhaler is revolutionizing the medical cannabis industry by providing consistent and precise treatment at pharmaceutical standards. With the Syqe Inhaler, healthcare providers and patients can know precisely what dosage of medical cannabis is administered for treatment. For the first time ever, the amount of THC in the bloodstream can be accurately controlled in a consistent, repeatable and completely non-invasive fashion.
Syqe’s technology is supported by controlled clinical trials with patients suffering from chronic pain and was proven effective in reducing VAS score, providing rapid pain relief while reducing psychoactive effects, allowing patients to resume normal daily activities. The Syqe Inhaler is used with preloaded cartridges of medical cannabis produced under pharmaceutical standards.
Through this partnership, Canadian patients and doctors will have access to Syqe’s clinically tested medical cannabis solution, advancing the company’s mission to ease the suffering of as many patients as possible dealing with chronic conditions.
“Syqe’s goal since inception has been to bring relief to as many patients as possible in the fastest possible way, and we spent eight years developing the Syqe Inhaler to ensure that when introduced, it would make a significant positive impact on patients’ lives,” says Perry Davidson, Syqe CEO and Founder. “We have been searching for a partner that is truly focused on the medical side of cannabis. We are thrilled to be working with TerrAscend to share our groundbreaking technology with a progressive market at the forefront of medical cannabis treatment.”
